Parkinson's Treatment Stocks
3840 views
Rate Now: 1 2 3 4

average rating: 3.00 / 3 ratings
Created by Guest
DESCRIPTION:

Date updated:04-26-2007

There are many companies researching treatments and cures for this degenerative disorder of the central nervous system that impairs motor skills and speech. Here are some of them.

symbol name last price % change open
  • +
  • TEVA
    Teva Pharmaceutic
  • $53.16
  • -0.21%
  • $53.70

Teva Pharmaceutical Industries Ltd. (TEVA), an Israeli based company which was founded in 1901, develops and manufactures a variety of pharmaceuticals. They received approval from the U.S. Food and Drug Administration for AZILECT® (rasagiline tablets) as a treatment for Parkinson's disease. P/E is 54 and PEG is 1.1. The stock has been paying dividends quarterly and yields 1%.

People owning TEVA also tend to own: ACEBACBSXCSCODISFGES

TheStreet.com Rating: A What is this?

  • +
  • CEGE
    Cell Genesys
  • $0.36
  • 0.00%
  • $N/A

Cell Genesys, Inc. (CEGE) is an investor in Ceregene, which developed CERE-120, its lead program for Parkinson's disease. Earnings for CEGE are negative and the price sales ratio is an extremely high 225.

People owning CEGE also tend to own: CAMPELNKFCELIDIXJBLUTALKTIE

TheStreet.com Rating: No Rating What is this?

  • +
  • NVS
    Novartis Ag Ads
  • $55.85
  • +0.99%
  • $55.81

Novartis AG (NVS), a very large Swiss pharmaceutical company, has developed Comtan® (entacapone), a medication for the treatment of Parkinson's Disease. P/E is 19 and the PEG is 1.5. Yield is 1.6%.

People owning NVS also tend to own: ANNAUYBACBHIERICFGE

TheStreet.com Rating: B What is this?

  • +
  • ACAD
    Acadia Pharmaceut
  • $1.35
  • +2.27%
  • $1.34

Acadia Pharmaceuticals Inc. (ACAD), based in San Diego, is working on ACP-103 in patients with Parkinson's disease suffering from treatment-induced psychosis. Negative earnings, P/S of 53.

People owning ACAD also tend to own: ABPIAGIXAVGNCOLYDEPOMNTANABI

TheStreet.com Rating: D- What is this?

  • +
  • SNY
    Sanofi-aventis Sa
  • $39.46
  • +2.15%
  • $39.26

Sanofi-Aventis (SNY) is the third largest pharmaceutical company in the world. It is working on SR57667B for treatment of symptoms. PE IS 23, PEG is 2.3. Yield is 2.1%.

People owning SNY also tend to own: AEGAZBRK-BINGINTCOPA.VORCL

TheStreet.com Rating: B What is this?

  • +
  • SKYE
    N/a
  • $25.55
  • 0.00
  • $25.55

SkyePharma plc (SKYE) developed once-daily formulation of Requip® utilizing SkyePharma's Geomatrix™ technology. Requip is used for Parkinson's treatment. No earnings, P/S is 3.5.

People owning SKYE also tend to own: CYTRFLMLISISGEGLWJNJMIC

TheStreet.com Rating: No Rating What is this?

  • +
  • VRX
    Valeant Pharma In
  • $33.11
  • +0.79%
  • $32.83

Valeant Pharmaceuticals International (VRX) markets Zelapar® [selegiline HCl] Orally Disintegrating Tablets, a once-daily adjunct therapy for Parkinson’s disease patients being treated with levodopa/carbidopa. Forward P/E of 16.6 and a PEG of .8. Yields 1.7%.

People owning VRX also tend to own: CTOFURGEHLGETIMBRXPTEKPWEI

TheStreet.com Rating: B- What is this?

Portfolio not tracked!

05/01/2007 17:23 PM CDT Asked by Dark Knight 212
In addition to the companies you listed, I suggest you look at the British biotech firm Amarin (AMRN - Last Trade: 0.68 Change: -0.025). AMRN has ongoing Phase II clinical testing of Miraxion and AMR-101 both for the treatment of Parkinson's Disease.

Amarin recently dropped more than 85 percent on poor statistical results in Phase III tests of Miraxion for Huntington's disease.

After an 85% drop the stock bears watching because they have 4 other drugs in their pipeline that are on track, 29 million dollars cash, no debt and they have 30% insider and 25% institutional ownership.

Management will be providing an update to investors on the progress, plans and timelines for Amarin’s pipeline of products at two upcoming investor conferences. Rodman & Renshaw on May 15th and Banc of America on June 1st. Both of these investor presentations will be webcast so you can listen in. More information about the specifics of the webcasts will be issued in advance of each conference.

Full Disclosure: I own AMRN.

04/27/2007 03:59 AM CDT Asked by mock portfolio
I love lists like this...

ADD YOUR COMMENTS:

Black Friday Short-Squeeze Oppor...

By Jonas Elmerraji Posted on Nov. 25, 2009 With Thanksgiving fast approaching, retailers have one thing on their collective minds: Black Friday. After all, the day, whi...

11.25.09 | 13:33 PM
Dividend Stocks for the Week

By Jonas Elmerraji Posted on Nov. 24, 2009 Don’t dismiss dividends right now. While stocks may have made significant strides in the rally that’s taken hold of the m...

11.24.09 | 11:36 AM
This Week's 'Barron's' Roundup

By Roberto Pedone Posted on Nov. 24, 2009 10 Terrific Dividend Stocks: This Barron’s article highlights 10 high-quality dividend-paying stocks for investors who’re ...

11.24.09 | 08:05 AM
Rocket Stocks for the Week

By Jonas Elmerraji Posted on Nov. 23, 2009 As well as broad-based indexes have performed in the last few months, Stockpickr's weekly Rocket Stocks list has managed to d...

11.23.09 | 10:34 AM
more articles
General market Technical Analysi...
11.14.07 | 22:55 PM From author ZA
The Presidential/Political Thread
01.02.08 | 08:05 AM From author Dave Cox
Full Disclosure
11.09.08 | 12:30 PM From author alchemist
The YouTube Exchange
07.22.09 | 17:45 PM From author Rawbrrt
more forums
today 's lists
TheStreet.com TV Videos

These are some of the stocks mentioned on TheStreet.com TV recently. Click the URL below each stock to watch the videos. more

Earnings Announcements

The market is closed tomorrow (11/26/2007). Here is a list of some of the companies that will report earnings on Friday (Nov. 27, 2009). For some of the companies below... more

Stocks With Unusual Option Activity

Unusually active options can often indicate that a major event in a stock is about to take place, or that unsophisticated investors (using options in lieu of leverage) are ... more